The Cardiovascular Protective Effects of Febuxostat in Peritoneal Dialysis Patients
NCT ID: NCT02338128
Last Updated: 2019-07-24
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
50 participants
OBSERVATIONAL
2015-01-31
2018-01-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Lowering-hyperuricemia Treatment on Cardiovascular Outcomes in Peritoneal Dialysis Patients
NCT03200210
Compare the Renal Protective Effects of Febuxostat and Benzbromarone
NCT02338323
Effects of Febuxostat on Adipokines and Kidney Disease in Diabetic Chronic Kidney Disease
NCT01350388
Use of Febuxostat in Hyperuricemia Among Hemodialysis Patients
NCT03149939
Effect of Hyperuricaemia on Chronic Renal Disease
NCT03425708
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
2. Heart failure (stage IV, NYHA), unstable angina, acute stroke
3. Severe lung disease or cancer
4. unable to sign the informed consent form or disagree following-up.
18 Years
75 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Shanghai 10th People's Hospital
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Ai Peng
Chief of department of Nephrology & Rheumatology
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Ling Wang, MD, PhD
Role: STUDY_CHAIR
Department of Nephrology & Rheumatology, Shanghai Tenth People's Hospital
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Department of Nephrology & Rheumatology, Shanghai Tenth People's Hospital
Shanghai, Shanghai Municipality, China
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
FPD2015
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.